These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36643309)

  • 21. Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
    Guancial EA; Kilari D; Xiao GQ; Abu-Farsakh SH; Baran A; Messing EM; Kim ES
    PLoS One; 2016; 11(5):e0155503. PubMed ID: 27187160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy.
    Nielsen N; Wrist Lam G; Fabrin K; Holt P; Thind PO; Jensen JB
    Scand J Urol; 2019 Aug; 53(4):213-216. PubMed ID: 31174449
    [No Abstract]   [Full Text] [Related]  

  • 23. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
    Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
    BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report.
    Rosenblatt R; Johansson M; Alamdari F; Sidiki A; Holmström B; Hansson J; Vasko J; Marits P; Gabrielsson S; Riklund K; Winqvist O; Sherif A
    World J Urol; 2017 Jun; 35(6):921-927. PubMed ID: 27738804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chick Chorioallantoic Membrane as a Patient-Derived Xenograft Model for Uveal Melanoma: Imaging Modalities for Growth and Vascular Evaluation.
    Tsimpaki T; Bechrakis NE; Seitz B; Kraemer MM; Liu H; Dalbah S; Sokolenko E; Berchner-Pfannschmidt U; Fiorentzis M
    Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chick Chorioallantoic Membrane (CAM) Assays as a Model of Patient-Derived Xenografts from Circulating Cancer Stem Cells (cCSCs) in Breast Cancer Patients.
    Pizon M; Schott D; Pachmann U; Schobert R; Pizon M; Wozniak M; Bobinski R; Pachmann K
    Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
    Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
    Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
    Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
    Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive value of phenotypic signatures of bladder cancer response to cisplatin-based neoadjuvant chemotherapy.
    Hensley PJ; Kyprianou N; Purdom MS; He D; DiCarlo V; Wang C; James AC
    Urol Oncol; 2019 Sep; 37(9):572.e1-572.e11. PubMed ID: 31326313
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Impact of Primary Versus Secondary Muscle-invasive Bladder Cancer at Diagnosis on the Response to Neoadjuvant Chemotherapy.
    D'Andrea D; Shariat SF; Soria F; Mari A; Mertens LS; Di Trapani E; Carrion DM; Pradere B; Pichler R; Filippot R; Grisay G; Del Giudice F; Laukhtina E; Paulnsteiner D; Krajewski W; Vallet S; Maggi M; De Berardinis E; Álvarez-Maestro M; Brönimann S; Di Maida F; van Rhijn BWG; Hendricksen K; Moschini M;
    Eur Urol Open Sci; 2022 Jul; 41():74-80. PubMed ID: 35813257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy.
    Black AJ; Zargar H; Zargar-Shoshtari K; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Griffin J; Montgomery JS; Vasdev N; Yu EY; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Grivas P; Stephenson AJ; Shah JB; van Rhijn BW; Spiess PE; Daneshmand S; Sridhar SS; Black PC
    Urol Oncol; 2020 Jan; 38(1):3.e17-3.e27. PubMed ID: 31676278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
    Shi H; Zhang W; Bi X; Wang D; Xiao Z; Guan Y; Guan K; Tian J; Bai H; Hu L; Cao C; Jiang W; Hu Z; Zhang J; Chen Y; Zheng S; Feng X; Li C; Li Y; Ma J; Liu Y; Zhou A; Shou J
    Cancer Res Treat; 2021 Oct; 53(4):1156-1165. PubMed ID: 33592141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of immunohistochemical markers of tumor subtype with response to neoadjuvant chemotherapy and survival in patients with muscle-invasive bladder cancer.
    Razzaghdoust A; Ghajari M; Basiri A; Torbati PM; Jafari A; Fattahi MR; Salahi M; Mofid B
    Investig Clin Urol; 2021 May; 62(3):274-281. PubMed ID: 33943049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer.
    Martini A; Jia R; Ferket BS; Waingankar N; Plimack ER; Crabb SJ; Harshman LC; Yu EY; Powles T; Rosenberg JE; Pal SK; Vaishampayan UN; Necchi A; Wiklund NP; Mehrazin R; Mazumdar M; Sfakianos JP; Galsky MD
    Cancer; 2019 Sep; 125(18):3155-3163. PubMed ID: 31150110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishment of xenografts of urological cancers on chicken chorioallantoic membrane (CAM) to study metastasis.
    Hu J; Ishihara M; Chin AI; Wu L
    Precis Clin Med; 2019 Sep; 2(3):140-151. PubMed ID: 31598385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers.
    Moon HG; Oh K; Lee J; Lee M; Kim JY; Yoo TK; Seo MW; Park AK; Ryu HS; Jung EJ; Kim N; Jeong S; Han W; Lee DS; Noh DY
    Breast Cancer Res Treat; 2015 Nov; 154(1):13-22. PubMed ID: 26438141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.
    Jäger W; Xue H; Hayashi T; Janssen C; Awrey S; Wyatt AW; Anderson S; Moskalev I; Haegert A; Alshalalfa M; Erho N; Davicioni E; Fazli L; Li E; Collins C; Wang Y; Black PC
    Oncotarget; 2015 Aug; 6(25):21522-32. PubMed ID: 26041878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nomogram based on baseline clinicopathological characteristics for predicting bladder cancer-specific survival to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
    Font A; Domenech M; Buisan O; Lopez H; González A; Etxaniz O; Matas M; Elias X; Gomez M; Figols M; Horneros J; Pardo JC; Notario L; Ruiz de Porras V; Perez I; Areal J; Esteve A
    World J Urol; 2022 Nov; 40(11):2627-2634. PubMed ID: 36107212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival.
    Rosenblatt R; Lorentzi G; Bahar M; Asad D; Forsman R; Johansson M; Shareef M; Alamdari F; Bergh A; Winqvist O; Sherif A
    Scand J Urol; 2020 Feb; 54(1):46-51. PubMed ID: 31960752
    [No Abstract]   [Full Text] [Related]  

  • 40. Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab.
    Necchi A; de Jong JJ; Raggi D; Briganti A; Marandino L; Gallina A; Bandini M; Dabbas B; Davicioni E; Capitanio U; Montorsi F; Seiler R; Wright JL; Lotan Y; Black PC; Gibb EA
    Eur Urol; 2021 Aug; 80(2):149-159. PubMed ID: 33785257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.